Improving Insulin Resistance To Treat Non-Alcoholic Fatty Liver Disease: A Pilot Study

Withdrawn before enrolling · Phase 1

Conditions studied: Non-alcoholic Fatty Liver Disease (NAFLD)

In brief

Metformin is being compared to exercise and diet modifications. The researchers are interested in learning if the addition of metformin to lifestyle modifications is more helpful in treating the condition or disorder. Although metformin is FDA approved to treat type 2 diabetes, it is not FDA approved for the treatment of Non-alcoholic fatty liver (NAFLD) and is considered investigational for the purpose of this study.

Key facts

Study ID

NCT02457286

Run by

Northwell Health

People needed

0

Starts

2015-06-01

Expected to finish

2017-07-01

Last updated by the study team

2017-07-28

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• subjects between ages 18-80
• diagnosed with NAFLD by alanine aminotransferase
• (ALT) levels >1.5x the upper limit of normal with an otherwise nondiagnostic hepatic serology workup, ultrasound evidence, and/or histologically confirmed NAFLD within the past 1 year.
• The upper limit of normal for ALT will be defined as 35 U/L in males and 19 U/L in females

You may not qualify if…

• A prior history of diabetes
• Failure to meet criteria for HbA1C screening
• Evidence of hepatic disorders
• Use of insulin or oral hypoglycemic agents
• eGFR <30
• Blood transfusion within past 3 months
• Steroid use in the past 6 months
• Excessive alcohol use (more than 20g per day in women and more than 30g per day in men)
• Acute or unstable congestive heart failure
• Age >80 years old
• Lactic acidosis
• Inability to consent due to cognitive impairment.
• Pregnancy

Where it is running

• North Shore Hospital — Manhasset, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.